A team of international researchers has pinpointed a key driver behind the growth of Posterior Fossa Type A (PFA) ependymoma, a particularly aggressive and often fatal childhood brain tumor. The study, published in the journal Nature, reveals that male hormones, known as androgens, fuel the proliferation of these tumors – a finding that could pave the way for new, targeted treatments. This discovery is especially significant because PFA ependymoma has historically lacked clear genetic markers, making it difficult to develop effective therapies.
For years, clinicians have observed a troubling trend: boys are diagnosed with PFA ependymoma more frequently than girls, and their survival rates are lower. Understanding the reasons behind this disparity has been a major challenge. This new research suggests that androgens play a critical role, keeping tumor cells in a less-developed, rapidly growing state. The findings offer a biological explanation for these long-recognized sex differences and open the door to exploring anti-androgen therapies as a potential treatment strategy for this devastating disease.
Unraveling the Mystery of PFA Ependymoma Growth
PFA ependymoma typically affects young children, often under the age of three, and arises in a region of the brain called the posterior fossa. The tumor’s location can make complete surgical removal difficult, and traditional chemotherapy and radiation treatments have shown limited success. “What drives PFA ependymoma’s growth has remained a mystery for quite some time,” explained Dr. Jiao Zhang, co-first author of the study and assistant professor of pediatrics – hematology/oncology at Baylor College of Medicine and Texas Children’s Hospital. “As opposed to other lethal brain tumors, this cancer lacks clear genetic drivers, which has delayed the development of effective therapies.”
Researchers from Baylor College of Medicine, Texas Children’s Hospital, McGill University, and the University of Pittsburgh School of Medicine collaborated on the study. They began by investigating whether differences in sex chromosomes (XX for females, XY for males) or sex hormones were responsible for the observed vulnerability of boys. Through experiments using animal models and cancer cells grown in the lab, the team discovered that androgens were the primary culprit. They found that PFA ependymoma cells in males were less developed than those in females, and that supplementing with androgens promoted tumor growth and maintained this less-developed state.
The Role of Androgens and Brain Cell Development
The research builds on previous observations that female brain cells, at similar developmental stages, appear more mature than those of males. The team’s work suggests that this difference in development extends to PFA ependymoma cells. “We found that, as it occurs in normal brain cells, PFA ependymoma cells are less developed in males than in female patients,” Dr. Zhang said. “This difference is driven by androgens, which maintain these tumor cells in a less-developed, growth‑prone state.” Importantly, the study found no evidence that chromosomal factors contributed to the difference, and female sex hormones did not significantly impact PFA cell growth.
Dr. Claudia Kleinman, a co-corresponding author and professor in the department of human genetics at McGill University’s Lady Davis Institute for Medical Research, emphasized the significance of this finding. “Our study provides a biological basis for understanding the long-recognized sex differences in PFA ependymoma,” she stated. The researchers believe this understanding could be crucial in developing more effective treatments tailored to the specific biological characteristics of the tumor.
Potential for Anti-Androgen Therapies
The implications of this research are potentially far-reaching. The team suggests that anti-androgen therapies – medications that block the effects of male hormones – could be a promising new approach to treating PFA ependymoma. “We reveal a previously unknown link between early hormone exposure and tumor formation, and we suggest that anti-androgen therapies could be a promising treatment option for this devastating disease,” said Dr. Kulandaimanuvel Antony Michealraj, a co-corresponding author and assistant professor of neurological surgery at the University of Pittsburgh School of Medicine.
Dr. Michael D. Taylor, a co-corresponding author and professor of pediatrics – hematology/oncology and of neurosurgery at Baylor and staff neurosurgeon at Texas Children’s, added that the findings have “potential clinical implications as they suggest that androgen‑blocking therapies may represent a rational direction for future targeted treatment strategies.” While further research is needed to determine the safety and efficacy of anti-androgen therapies in children with PFA ependymoma, the study provides a strong rationale for exploring this avenue.
The researchers are now focused on investigating how best to translate these findings into clinical trials. They are also exploring potential biomarkers that could aid identify patients who are most likely to benefit from anti-androgen treatment. The ultimate goal is to improve survival rates and quality of life for children diagnosed with this challenging cancer. The study’s findings, published in Nature, represent a significant step forward in understanding and combating PFA ependymoma.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. This proves essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The research team plans to continue investigating the role of androgens in PFA ependymoma and to explore potential therapeutic strategies. Updates on clinical trials and further research findings will be available through Baylor College of Medicine and the participating institutions. We encourage readers to share this information and to support ongoing research into childhood cancers.
